Bioengineering tools—including biomaterial scaffolds, organoid systems, and tissue-targeted delivery mechanisms—enable direct interrogation of immune aging at the cellular and tissue level. These approaches bridge mechanistic understanding and therapeutic translation, offering specific pathways to modulate age-related immune dysfunction.
Key Points
- Extracellular matrix engineering reveals immune cell behavior in aging contexts
- Organoid and microphysiological systems model immune aging outside the body
- Tissue-targeted delivery improves vaccine and drug efficacy in older populations
Longevity Analysis
The immune system's capacity to defend against infection and clear senescent cells directly determines disease risk and healthspan. Age-related immune dysfunction—characterized by reduced responsiveness to threats and impaired clearance of damaged cells—accelerates pathology across multiple systems. These bioengineering platforms shift immune research from population-level observation to mechanistic interrogation at cellular resolution, enabling rational design of interventions that restore function rather than merely stimulate response. For practitioners, this work clarifies what specifically fails in aging immunity and provides tools to test whether candidate therapies actually restore the underlying capacity.
Original published by Nature Aging, by Janko Ž. Nikolich.